GSK plc

GSK plc reported that investment manager Dodge & Cox has increased its stake in the company. Dodge & Cox's total voting rights in GSK plc now stand at 5.01%, up from a previous position of 4.93%. This change, representing 203,320,168 voting rights, crossed the 5% threshold on June 23, 2026.

GSK plc reported an insider transaction involving Maya Martinez-Davis, President, US. She acquired 9.4103 American Depositary Shares (ADS) at a price of $50.7400 per share. This acquisition was part of her GSK Executive Supplemental Savings Plan account and occurred on June 22, 2026, on the New York Stock Exchange.

GSK plc announced that its indirect wholly-owned subsidiary, Harmony Row Acquisition Co., has commenced a tender offer to acquire all outstanding Class A and Class B shares of Nuvalent, Inc. for $124.00 per share in cash. This offer is made under an Agreement and Plan of Merger dated June 9, 2026. Nuvalent's Board of Directors has recommended that its stockholders accept the offer, which is set to expire on July 14, 2026. The acquisition is subject to customary closing conditions, including a minimum tender condition and regulatory approvals.

GSK plc announced that several of its Independent Non-Executive Directors have purchased company shares. Elizabeth McKee Anderson acquired 1,550 Ordinary Shares on the London Stock Exchange. Additionally, Charles Bancroft, Dr Anne Beal, Dr Hal Dietz, Dr Jeannie Lee, and Dr Vishal Sikka each purchased American Depositary Shares (ADS) on the New York Stock Exchange.

GSK plc announced the repurchase of 1,001,889 of its ordinary shares between June 15 and June 19, 2026, as part of its existing buyback program. These shares were acquired through Citigroup Global Markets Limited at varying prices and will be held as Treasury shares. Since May 11, 2026, the company has repurchased a total of 8,448,125 ordinary shares. Following these transactions, GSK holds 269,826,411 ordinary shares in treasury, representing 6.67% of the total voting rights.

GSK plc announced the repurchase of 1,001,889 of its ordinary shares between June 15 and June 19, 2026, as part of its ongoing buyback program. These shares were purchased through Citigroup Global Markets Limited at varying prices. Since May 11, 2026, the company has bought back a total of 8,448,125 ordinary shares. Following these transactions, GSK now holds 269,826,411 shares in treasury, representing 6.67% of the total voting rights.

GSK plc and Spero Therapeutics announced that the US FDA has approved Utebzi (tebipenem pivoxil), an oral antibiotic for complicated urinary tract infections (cUTIs) in adults with limited or no alternative oral treatment options. This marks the first and only oral carbapenem antibiotic approved in the US for cUTIs, including pyelonephritis. The approval is supported by the PIVOT-PO phase III trial, which demonstrated non-inferiority compared to intravenous treatment. Utebzi is expected to be available to US patients by the end of 2026, offering a potential solution to reduce reliance on hospital-based intravenous care for resistant infections.

GSK plc announced the purchase of 1,112,424 of its ordinary shares between June 8 and June 12, 2026, as part of its ongoing buyback program. These shares will be held as treasury shares. Since May 11, 2026, the company has repurchased a total of 7,346,236 ordinary shares. Following these purchases, GSK holds 268,724,522 ordinary shares in treasury, representing 6.64% of voting rights.

GSK announced that its drug momelotinib has been granted Orphan Drug Designation by both the US Food and Drug Administration and the European Medicines Agency for the treatment of VEXAS syndrome. VEXAS syndrome is a rare, life-threatening haemato-inflammatory condition for which there are currently no approved treatments. This designation supports the ongoing development efforts and regulatory evaluations for momelotinib, which is already approved for myelofibrosis. A phase II/III ATLAS trial evaluating momelotinib's efficacy and safety in VEXAS syndrome is underway, with its design to be presented at the 2026 European Hematology Association Congress.

GSK plc reported that several Persons Discharging Managerial Responsibilities (PDMRs) and a Person Closely Associated (PCA) acquired ordinary shares under the Company's Share Reward Plan. These transactions, totaling 108 ordinary shares, occurred on June 9, 2026, on the London Stock Exchange at a price of £18.8393 per share. The acquisitions involved both partnership and matching shares for each individual, including the Chief Financial Officer and other senior executives.